Shares of Neumora Therapeutics Inc. (NMRA), a clinical-stage biopharmaceutical company focused on brain diseases, are down over 50% from their 52-week high of $21, recorded in March of this year, and trade around $9. With several key clinical trial events on the horizon, it could be worth keeping an eye on this stock.
The company's lead drug candidate, Navacaprant (NMRA-140), a kappa opioid receptor (KOR) antagonist, is currently being evaluated in a pivotal Phase 3 program for Major Depressive Disorder, dubbed KOASTAL.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.